VERA Class A Vera Therapeutics, Inc. - Class A Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 10, 2026
$30.42
· of 52w range
· above low
· to high
$23.0552w low
$56.0552w high
P/E
-10.9
EPS
$-4.66
your badges
52W Range
$23–$56
Analyst Rating
BUY
Price Target
$78
P/E
-10.9
ROE
-55.9%
Net Profit Margin
·
Your badge strip is empty — pin a metric anywhere on this page.
VERA Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$30.42
P/E
-10.9
EPS
$-4.66
ROE
-55.9%
52W Range
$23–$56
VERA Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
EPS$-4.662021-12-31 → 2025-12-31
Free Cash Flow$-242M2022-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | VERA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | -10.95Y avg ≈-10.0 | ≈-10.0 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | VERA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| ROA | -43.1%5Y avg ≈-54.4% | ≈-54.4% | -40.3% | Weak | |
| ROE | -55.9%5Y avg ≈-63.2% | ≈-63.2% | -54.5% | Weak | |
| ROIC | -52.2%5Y avg ≈-69.8% | ≈-69.8% | -52.2% | In line |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | VERA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 10.95Y avg ≈12.5 | ≈12.5 | 13.0 | Below avg | |
| Quick Ratio | 13.45Y avg ≈12.1 | ≈12.1 | 6.6 | Strong liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-14.3%
Next Report
Nov 03, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 3, 2026 | $-1.52 | $-1.61 | 5.5% |
| March 31, 2026 | $-1.69 | $-1.35 | -24.9% | |
| Dec. 31, 2025 | $-1.39 | $-1.31 | -6.3% | |
| Sept. 30, 2025 | $-1.26 | $-1.16 | -8.8% | |
| June 30, 2025 | $-1.20 | $-0.84 | -43.2% | |
| March 31, 2025 | $-0.81 | $-0.75 | -8.0% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| R&D Expense | $215M | $126M | $78M | $69M | $22M | $45M | |
| SG&A Expense | $100M | $41M | $24M | $22M | $12M | $4M | |
| Operating Expenses | $315M | $167M | $102M | $91M | $34M | $52M | |
| Operating Income | $-315M | $-167M | $-102M | $-91M | $-34M | $-52M | |
| Interest Expense | · | · | $4M | $992.0K | $20.0K | $166.0K | |
| Interest Income | $24M | $21M | $8M | $2M | $15.0K | $8.0K | |
| Other Non-op | $16M | $15M | $6M | $2M | $2M | $-1M | |
| Pretax Income | $-300M | $-152M | $-96M | $-89M | $-33M | $-53M | |
| Income Tax | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $-1.0K | |
| Net Income | $-300M | $-152M | $-96M | $-89M | $-33M | $-53M | |
| EPS (Basic) | $-4.66 | $-2.75 | $-2.25 | $-3.35 | $-2.43 | · | |
| EPS (Diluted) | $-4.66 | $-2.75 | $-2.25 | $-3.35 | $-2.43 | · | |
| Shares (Basic) | 64,233,814 | 55,326,680 | 42,707,072 | 26,570,676 | 13,435,706 | · | |
| Shares (Diluted) | 64,233,814 | 55,326,680 | 42,707,072 | 26,570,676 | 13,435,706 | · | |
| EBITDA | $-315M | $-167M | $-106M | $-92M | $-34M | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $355M | $93M | $46M | $43M | $80M | $54M | |
| Short-term Investments | $360M | $548M | $115M | $71M | $0 | · | |
| Prepaid Expense | $14M | $10M | $11M | $11M | $3M | $557.0K | |
| Other Current Assets | $3M | $1M | $2M | $719.0K | $480.0K | $392.0K | |
| Current Assets | $729M | $651M | $172M | $126M | $83M | $54M | |
| PP&E (Net) | $1M | $960.0K | $92.0K | $51.0K | $0 | · | |
| Other Non-current Assets | $6M | · | · | · | · | · | |
| Total Assets | $735M | $656M | $176M | $131M | $84M | $55M | |
| Accounts Payable | $22M | $8M | $11M | $12M | $1M | $909.0K | |
| Accrued Liabilities | $32M | $16M | $9M | $11M | $6M | $535.0K | |
| Current Liabilities | $53M | $25M | $22M | $26M | $8M | $2M | |
| Capital Leases | $2M | $2M | $1M | $4M | $0 | · | |
| Other Non-current Liabilities | $2M | · | · | · | · | · | |
| Total Liabilities | $130M | $79M | $74M | $55M | $14M | $4M | |
| Long-term Debt | $75M | $51M | $50M | $25M | $5M | $0 | |
| Common Stock | $71.0K | $64.0K | $44.0K | $28.0K | · | · | |
| Retained Earnings | $-761M | $-461M | $-309M | $-213M | $-124M | $-91M | |
| AOCI | $786.0K | $393.0K | $251.0K | $-224.0K | $0 | · | |
| Stockholders' Equity | $605M | $577M | $102M | $77M | $70M | $-89M | |
| Liabilities + Equity | $735M | $656M | $176M | $131M | $84M | $55M |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| D&A | $468.0K | $105.0K | $21.0K | $-846.0K | $176.0K | $251.0K | |
| Stock-based Comp | $38M | $21M | $11M | $9M | $3M | $331.0K | |
| Deferred Tax | · | $0 | $0 | $0 | $0 | $0 | |
| Restructuring | · | · | · | · | $0 | $3M | |
| Other Non-cash | $20M | $-3M | $-4M | $13M | $6M | · | |
| Operating Cash Flow | $-241M | $-135M | $-92M | $-68M | $-24M | $-35M | |
| CapEx | $630.0K | $972.0K | $63.0K | $62.0K | $0 | $99.0K | |
| Investing Cash Flow | $194M | $-425M | $-39M | $-71M | $-4M | $-42.0K | |
| Stock Issued | · | · | · | $2M | $0 | · | |
| Stock Repurchased | $0 | $13.0K | $0 | · | · | · | |
| Net Stock Activity | $0 | $-13.0K | · | $2M | $51M | · | |
| Financing Cash Flow | $309M | $607M | $134M | $102M | $54M | $85M | |
| Net Change in Cash | $262M | $47M | $2M | $-36M | $26M | $50M | |
| Taxes Paid | $17.0K | $1.0K | $1.0K | · | · | · | |
| Free Cash Flow | $-242M | $-136M | $-92M | $-68M | · | · | |
| Levered FCF | · | · | $-96M | $-69M | · | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| ROA | -43.1% | -36.6% | -62.5% | -82.8% | -47.2% | · | |
| ROE | -55.9% | -35.1% | -85.2% | -97.5% | -42.1% | · | |
| ROIC | -52.2% | -29.0% | -100.3% | -118.2% | -49.4% | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 13.6 | 25.7 | 7.7 | 4.9 | 10.7 | · | |
| Quick Ratio | 13.4 | 25.3 | 7.2 | 4.5 | 10.4 | · | |
| Interest Coverage | · | · | -26.9 | -91.6 | -1720.1 | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash Flow / Share | $-3.75 | $-2.43 | $-2.16 | $-2.54 | · | · | |
| EPS (TTM) | $-4.66 | $-2.75 | $-2.25 | $-3.35 | $-2.43 | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Net Income TTM | $-300M | $-152M | $-96M | $-89M | $-33M | · | |
| P/E | -10.9 | -15.4 | -6.8 | -5.8 | -11.0 | · | |
| Earnings Yield | -9.2% | -6.5% | -14.6% | -17.3% | -9.1% | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $60M | $86M | $59M | $56M | $58M | $41M | $33M | $40M | $29M | $23M | $16M | $16M | $25M | $27M | $20M | $10M | |
| SG&A Expense | $52M | $39M | $35M | $27M | $22M | $16M | $16M | $9M | $8M | $8M | $6M | $6M | $6M | $7M | $6M | $5M | |
| Operating Expenses | $112M | $125M | $94M | $84M | $80M | $57M | $49M | $50M | $37M | $31M | $22M | $22M | $31M | $34M | $25M | $15M | |
| Operating Income | $-112M | $-125M | $-94M | $-84M | $-80M | $-57M | $-49M | $-50M | $-37M | $-31M | $-22M | $-22M | $-31M | $-34M | $-25M | $-15M | |
| Interest Expense | · | · | · | · | · | · | · | · | $2M | $2M | $943.0K | $914.0K | $874.0K | $599.0K | $147.0K | $128.0K | |
| Interest Income | $5M | $6M | $6M | $6M | $6M | $7M | $7M | $5M | $5M | $4M | $2M | $2M | $2M | $894.0K | $567.0K | $263.0K | |
| Other Non-op | $3M | $4M | $3M | $4M | $4M | $6M | $5M | $3M | $4M | $3M | $2M | $2M | $1M | $1M | $565.0K | $204.0K | |
| Income Tax | · | · | · | · | · | · | · | · | · | · | · | · | · | $1.0K | $0 | $0 | |
| Net Income | $-109M | $-121M | $-91M | $-80M | $-77M | $-52M | $-43M | $-47M | $-34M | $-28M | $-20M | $-20M | $-30M | $-32M | $-25M | $-15M | |
| EPS (Basic) | $-1.52 | $-1.69 | $-1.39 | $-1.26 | $-1.20 | $-0.81 | $-0.72 | $-0.85 | $-0.62 | $-0.56 | $-0.45 | $-0.46 | $-0.80 | $-1.18 | $-0.91 | $-0.55 | |
| EPS (Diluted) | $-1.52 | $-1.69 | $-1.39 | $-1.26 | $-1.20 | $-0.81 | $-0.72 | $-0.85 | $-0.62 | $-0.56 | $-0.45 | $-0.46 | $-0.80 | $-1.18 | $-0.91 | $-0.55 | |
| Shares (Basic) | 71,838,008 | 71,476,595 | · | 63,847,055 | 63,789,303 | 63,671,558 | · | 54,898,297 | 54,728,552 | 50,971,933 | 44,363,419 | 44,269,772 | 37,667,566 | · | 27,215,874 | 27,078,450 | |
| Shares (Diluted) | 71,838,008 | 71,476,595 | · | 63,847,055 | 63,789,303 | 63,671,558 | · | 54,898,297 | 54,728,552 | 50,971,933 | 44,363,419 | 44,269,772 | 37,667,566 | · | 27,215,874 | 27,078,450 | |
| EBITDA | $-112M | $-125M | · | $-84M | $-80M | $-57M | · | $-50M | $-37M | $-33M | $-22M | $-22M | $-32M | · | $-25M | $-15M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $49M | $114M | $355M | $58M | $49M | $55M | $93M | $27M | $25M | $69M | $27M | $34M | $137M | $43M | $30M | $50M | |
| Short-term Investments | $450M | $482M | $360M | $440M | $508M | $535M | $548M | $326M | $359M | $335M | $132M | $147M | $60M | $71M | $84M | $82M | |
| Prepaid Expense | $28M | $19M | $14M | $14M | $15M | $16M | $10M | $11M | $10M | $13M | $12M | $10M | $7M | $11M | $11M | $10M | |
| Other Current Assets | $4M | $2M | $3M | $1M | $2M | $2M | $1M | $1M | $429.0K | $568.0K | $2M | $1M | $883.0K | $719.0K | $792.0K | $776.0K | |
| Current Assets | $527M | $616M | $729M | $511M | $571M | $606M | $651M | $364M | $395M | $416M | $172M | $191M | $204M | $126M | $125M | $142M | |
| PP&E (Net) | $813.0K | $945.0K | $1M | $1M | $1M | $1M | $960.0K | $368.0K | $155.0K | $81.0K | $34.0K | $40.0K | $45.0K | $51.0K | $56.0K | $21.0K | |
| Other Non-current Assets | $5M | $6M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Assets | $533M | $622M | $735M | $518M | $579M | $610M | $656M | $369M | $397M | $419M | $176M | $195M | $210M | $131M | $131M | $149M | |
| Accounts Payable | $15M | $14M | $22M | $18M | $13M | $9M | $8M | $5M | $5M | $5M | $12M | $13M | $5M | $12M | $7M | $7M | |
| Accrued Liabilities | $34M | $31M | $31M | $23M | $20M | $11M | $16M | $20M | $12M | $7M | $10M | $11M | $16M | $11M | $6M | $8M | |
| Current Liabilities | $48M | $45M | $53M | $42M | $34M | $22M | $25M | $26M | $18M | $15M | $25M | $27M | $24M | $26M | $16M | $17M | |
| Capital Leases | · | · | $2M | $2M | $2M | $2M | $2M | $3M | $455.0K | $919.0K | $2M | $3M | $3M | $4M | $4M | $5M | |
| Other Non-current Liabilities | $2M | $2M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Liabilities | $125M | $122M | $130M | $119M | $110M | $75M | $79M | $80M | $69M | $66M | $52M | $55M | $52M | $55M | $26M | $27M | |
| Long-term Debt | $75M | $75M | $75M | $75M | $74M | $51M | $51M | $50M | $50M | $50M | $25M | $25M | $25M | $25M | $5M | $5M | |
| Common Stock | $72.0K | $72.0K | $71.0K | $64.0K | $64.0K | $64.0K | $64.0K | $55.0K | $55.0K | $54.0K | · | · | · | $28.0K | · | · | |
| Retained Earnings | $-991M | $-882M | $-761M | $-670M | $-589M | $-513M | $-461M | $-418M | $-371M | $-337M | $-283M | $-263M | $-243M | $-213M | $-181M | $-156M | |
| AOCI | $-403.0K | $-156.0K | $786.0K | $881.0K | $527.0K | $654.0K | $393.0K | $1M | $-450.0K | $-173.0K | $-75.0K | $-142.0K | $-4.0K | $-224.0K | $-279.0K | $-152.0K | |
| Stockholders' Equity | $408M | $500M | $605M | $399M | $468M | $535M | $577M | $289M | $328M | $354M | $124M | $141M | $158M | $77M | $106M | $122M | |
| Liabilities + Equity | $533M | $622M | $735M | $518M | $579M | $610M | $656M | $369M | $397M | $419M | $176M | $195M | $210M | $131M | $131M | $149M |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $132.0K | $140.0K | $135.0K | $129.0K | $119.0K | $85.0K | $55.0K | $24.0K | $1M | $11.0K | $1M | $517.0K | $-506.0K | $-597.0K | $-152.0K | $-106.0K | |
| Stock-based Comp | $16M | $13M | $11M | $10M | $9M | $8M | $6M | $6M | $5M | $4M | $3M | $3M | $3M | $3M | $2M | $2M | |
| Other Non-cash | · | $1M | · | · | · | $-11M | · | · | · | $-8M | · | · | $2M | · | · | · | |
| Operating Cash Flow | $-100M | $-106M | $-70M | $-62M | $-55M | $-54M | $-39M | $-37M | $-25M | $-34M | $-23M | $-18M | $-26M | $-21M | $-18M | $-19M | |
| CapEx | $0 | $23.0K | $102.0K | $133.0K | $208.0K | $187.0K | $645.0K | $238.0K | $89.0K | $0 | $0 | $0 | $0 | $0 | $38.0K | $6.0K | |
| Investing Cash Flow | $33M | $-138M | $81M | $70M | $29M | $15M | $-221M | $38M | $-23M | $-219M | $16M | $-86M | $12M | $13M | $-2M | $-42M | |
| Stock Repurchased | · | · | $0 | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $2M | $4M | $286M | $797.0K | $20M | $2M | $326M | $739.0K | $3M | $277M | $297.0K | $432.0K | $108M | $21M | $908.0K | $48.0K | |
| Net Change in Cash | $-65M | $-240M | $297M | $9M | $-6M | $-38M | $65M | $2M | $-44M | $23M | $-6M | $-104M | $94M | $13M | $-20M | $-61M | |
| Free Cash Flow | · | $-107M | · | · | · | $-55M | · | · | · | · | · | · | $-26M | · | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -19.7% | -19.7% | · | -18.1% | -15.7% | -10.0% | · | -17.1% | -11.4% | -9.0% | -13.1% | -11.7% | -16.1% | · | -22.2% | -12.0% | |
| ROE | -25.0% | -23.4% | · | -23.3% | -19.2% | -11.6% | · | -22.6% | -14.4% | -11.1% | -17.5% | -15.4% | -20.6% | · | -25.8% | -13.9% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.9 | 13.6 | · | 12.2 | 17.0 | 27.7 | · | 13.8 | 21.4 | 28.6 | 7.0 | 7.1 | 8.7 | · | 7.9 | 8.2 | |
| Quick Ratio | 10.3 | 13.2 | · | 11.9 | 16.6 | 26.9 | · | 13.4 | 20.9 | 27.8 | 6.5 | 6.7 | 8.4 | · | 7.2 | 7.6 | |
| Interest Coverage | · | · | · | · | · | · | · | · | -19.5 | -16.3 | -23.1 | -24.0 | -35.8 | · | -171.7 | -117.6 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow / Share | · | $-1.49 | · | · | · | $-0.85 | · | · | · | $-0.66 | · | · | $-0.70 | · | · | · | |
| EPS (TTM) | $-5.86 | $-5.54 | · | $-3.99 | $-3.58 | $-3.00 | · | $-2.57 | $-2.17 | $-2.01 | $-2.89 | $-3.35 | $-3.44 | · | $-3.14 | $-2.59 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-402M | $-369M | · | $-252M | $-218M | $-175M | · | $-134M | $-108M | $-94M | $-103M | $-107M | $-102M | · | $-73M | $-56M | |
| P/E | -7.3 | -7.3 | · | -7.3 | -6.6 | -8.0 | · | -17.2 | -16.7 | -21.5 | -4.7 | -4.8 | -2.3 | · | -6.8 | -5.3 | |
| Earnings Yield | -13.7% | -13.8% | · | -13.7% | -15.2% | -12.5% | · | -5.8% | -6.0% | -4.7% | -21.1% | -20.9% | -44.3% | · | -14.7% | -19.0% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Net Income | $-300M | $-152M | $-96M | $-89M | $-33M |
| Diluted EPS | $-4.66 | $-2.75 | $-2.25 | $-3.35 | $-2.43 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Current Ratio | 13.6 | 25.7 | 7.7 | 4.9 | 10.7 |
| Quick Ratio | 13.4 | 25.3 | 7.2 | 4.5 | 10.4 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $-242M | $-136M | $-92M | $-68M | · |
Institutional owners (13F) 240 filers · $3.4B total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
240
Value held
$3.4B
New positions
34
Exited positions
35
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 34 (-19 vs prior Q) | 35 (+5 vs prior Q) | 99 (+4 vs prior Q) | 65 (+2 vs prior Q) | +4.5M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| BlackRock, Inc. | $246,636,382 | 5,747,760 | 7.34% | Shares |
| Avoro Capital Advisors LLC | $245,612,034 | 5,723,888 | 7.31% | Shares |
| VANGUARD GROUP INC | $180,805,107 | 3,570,401 | 5.38% | Shares |
| STATE STREET CORP | $178,024,407 | 4,148,786 | 5.30% | Shares |
| Deep Track Capital, LP | $171,640,000 | 4,000,000 | 5.11% | Shares |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $168,052,724 | 3,916,400 | 5.00% | Shares |
| Kynam Capital Management, LP | $124,012,432 | 2,890,059 | 3.69% | Shares |
| MORGAN STANLEY | $120,124,806 | 2,799,459 | 3.57% | Shares |
| Sofinnova Investments, Inc. | $119,889,982 | 2,793,987 | 3.57% | Shares |
| FMR LLC | $119,035,323 | 2,774,070 | 3.54% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $118,234,772 | 2,755,413 | 3.52% | Shares |
| Eversept Partners, LP | $94,949,961 | 2,212,770 | 2.82% | Shares |
| Logos Global Management LP | $94,402,000 | 2,200,000 | 2.81% | Shares |
| Integral Health Asset Management, LLC | $75,092,500 | 1,750,000 | 2.23% | Shares |
| Bellevue Group AG | $73,410,771 | 1,710,808 | 2.18% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $72,637,914 | 1,692,442 | 2.16% | Shares |
| ALLIANCEBERNSTEIN L.P. | $64,007,660 | 1,591,043 | 1.90% | Shares |
| GOLDMAN SACHS GROUP INC | $59,251,630 | 1,380,835 | 1.76% | Shares |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $55,585,829 | 1,295,405 | 1.65% | Shares |
| Pictet Asset Management Holding SA | $53,625,486 | 1,249,414 | 1.60% | Shares |
| DEUTSCHE BANK AG\ | $47,291,369 | 1,102,106 | 1.41% | Shares |
| Qube Research & Technologies Ltd | $46,479,211 | 1,083,179 | 1.38% | Shares |
| Woodline Partners LP | $42,954,498 | 1,001,037 | 1.28% | Shares |
| AMERICAN CENTURY COMPANIES INC | $37,170,604 | 866,243 | 1.11% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $27,585,680 | 642,873 | 0.82% | Shares |
| VOYA INVESTMENT MANAGEMENT LLC | $27,572,336 | 642,562 | 0.82% | Shares |
| GREAT POINT PARTNERS LLC | $25,781,873 | 600,836 | 0.77% | Shares |
| BANK OF AMERICA CORP /DE/ | $25,321,319 | 590,103 | 0.75% | Shares |
| NORTHERN TRUST CORP | $24,936,117 | 581,126 | 0.74% | Shares |
| BRAIDWELL LP | $24,232,307 | 564,724 | 0.72% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $23,386,508 | 545,013 | 0.70% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $22,650,172 | 527,853 | 0.67% | Shares |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $22,040,459 | 510,787 | 0.66% | Shares |
| Davern Capital Partners, LP | $21,404,881 | 498,832 | 0.64% | Shares |
| Candriam S.C.A. | $20,066,803 | 468,099 | 0.60% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $19,987,778 | 465,807 | 0.59% | Shares |
| Elmind Capital, LP | $18,730,987 | 436,518 | 0.56% | Shares |
| Rock Springs Capital Management LP | $18,347,629 | 427,584 | 0.55% | Shares |
| Balyasny Asset Management L.P. | $16,089,147 | 374,951 | 0.48% | Shares |
| ORBIMED ADVISORS LLC | $15,859,364 | 369,596 | 0.47% | Shares |
| Ikarian Capital, LLC | $13,302,100 | 310,000 | 0.40% | Shares |
| ARMISTICE CAPITAL, LLC | $12,873,000 | 300,000 | 0.38% | Shares |
| Nuveen, LLC | $12,804,773 | 298,410 | 0.38% | Shares |
| READYSTATE ASSET MANAGEMENT LP | $12,663,342 | 295,114 | 0.38% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $11,994,546 | 279,528 | 0.36% | Shares |
| MILLENNIUM MANAGEMENT LLC | $11,957,215 | 278,658 | 0.36% | Shares |
| CITIGROUP INC | $11,446,585 | 266,758 | 0.34% | Shares |
| UBS Group AG | $10,906,950 | 254,182 | 0.32% | Shares |
| Affinity Asset Advisors, LLC | $10,727,500 | 250,000 | 0.32% | Shares |
| Alphabet Inc. | $10,352,638 | 241,264 | 0.31% | Shares |
Activists & 5%+ owners 4 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Sofinnova Venture Partners X, L.P. ("SVP X"), Sofinnova Management X, L.P. ("SM X LP"), Sofinnova Management X-A, L.L.C. ("SM X LLC"), Dr. James I. Healy ("Healy"), Dr. Maha Katabi ("Katabi") | March 5, 2026 | 4.00% | Amendment | Passive investment | SEC |
| Longitude Capital Partners IV, LLC, Longitude Venture Partners IV, L.P., Longitude Prime Partners, LLC, Longitude Prime Fund, L.P., Patrick G. Enright, Juliet Tammenoms Bakker ×5 filings | Nov. 4, 2024 | · | Initial filing | · | SEC |
| Sofinnova Venture Partners X, L.P. (“SVP X”), Sofinnova Management X, L.P. (“SM X LP”), Sofinnova Management X-A, L.L.C. (“SM X LLC”), Dr. James I. Healy (“Healy”), Dr. Maha Katabi (“Katabi”) ×5 filings | March 26, 2024 | · | Initial filing | Passive investment | SEC |
| Abingworth LLP, Abingworth Bioventures 8, LP ×2 filings | April 7, 2022 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 25 insiders · 12 officers · 10 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Marshall Fordyce | PRESIDENT AND CEO | Sept. 15, 2026 M | 235,244 | 0 | 22 | $-9,730,927 |
| Sean Grant | CHIEF FINANCIAL OFFICER | Feb. 23, 2026 S | 114,181 | 0 | 1 | $-207,759 |
| David Lee Johnson | Chief Operating Officer | Feb. 23, 2026 S | 45,727 | 0 | 1 | $-108,266 |
| Joseph R Young | SVP, FINANCE, CHIEF ACCT OFFCR | Sept. 11, 2026 M | 80,754 | 0 | 2 | $-566,752 |
| Nancy Lee Boman | Chief Regulatory Officer | Aug. 3, 2026 A | 44,987 | 0 | 0 | $0 |
| Jane Wright Mitchell | Chief Legal Officer | March 23, 2026 A | 42,403 | 0 | 0 | $0 |
| Laurence Matthew Skelton | Chief Commercial Officer | Feb. 23, 2026 S | 64,218 | 0 | 1 | $-66,412 |
| Robert Brenner | Chief Medical Officer | Feb. 23, 2026 S | 50,947 | 0 | 1 | $-90,299 |
| William D. Turner | Chief Regulatory Officer | Feb. 23, 2026 S | 45,313 | 0 | 4 | $-1,445,710 |
| Jason S Carter | Chief Legal Officer | Nov. 21, 2025 S | 49,136 | 0 | 1 | $-107,496 |
| Celia Lin | Chief Medical Officer | Aug. 21, 2023 S | 11,010 | 0 | 0 | $0 |
| Joanne Curley | Chief Development Officer | Aug. 21, 2023 S | 26,962 | 0 | 0 | $0 |
| Kimball Hall | Director | May 21, 2026 A | · | 0 | 0 | $0 |
| Christy J. Oliger | Director | May 21, 2026 A | · | 0 | 0 | $0 |
| Andrew Cheng | Director | May 21, 2026 A | 17,488 | 0 | 0 | $0 |
| Scott W Morrison | Director | May 21, 2026 A | · | 0 | 0 | $0 |
| Michael Morrissey | Director | May 21, 2026 A | · | 0 | 0 | $0 |
| Beth C Seidenberg | Director | May 21, 2026 A | 131,553 | 0 | 0 | $0 |
| Christopher Hite | Director | March 5, 2026 A | · | 0 | 0 | $0 |
| Dr. Maha Katabi | Director | May 14, 2025 A | 2,793,987 | 0 | 0 | $0 |
| Kurt Von Emster | Director | May 18, 2021 C | 2,960,231 | 0 | 0 | $0 |
| COMMODORE CAPITAL LP | 10% owner | Jan. 10, 2024 S | 4,400,000 | 0 | 0 | $0 |
| Abingworth LLP | 10% owner | May 13, 2021 A | 2,960,231 | 0 | 0 | $0 |
| James R Meyers | · | May 21, 2026 A | · | 0 | 0 | $0 |
| Patrick G. Enright | · | May 21, 2026 A | 5,882 | 1 | 0 | $249,985 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 32 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0.63% | 9,072 NS | July 31, 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.58% | 89,811 NS | July 31, 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0.16% | 1,227 NS | July 31, 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.16% | 68,530 SH | Aug. 19, 2026 | Daily |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.15% | 5,108 SH | Oct. 1, 2026 | Daily |
| IBB · iShares Trust | 0.15% | 447,454 SH | Sept. 11, 2026 | Daily |
| IWO · iShares Trust | 0.14% | 601,982 SH | Sept. 11, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.08% | 367,755 SH | Aug. 19, 2026 | Daily |
| IWM · iShares Trust | 0.07% | 1,634,337 SH | Sept. 11, 2026 | Daily |
| BKSE · BNY Mellon ETF Trust | 0.07% | 1,841 NS | July 31, 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0.07% | 14,351 NS | July 31, 2026 | N-PORT |
| RSSL · Global X Funds | 0.07% | 30,600 NS | July 31, 2026 | N-PORT |
| ISCG · iShares Trust | 0.06% | 16,721 SH | Sept. 11, 2026 | Daily |
| ESML · iShares Trust | 0.05% | 45,356 SH | Sept. 11, 2026 | Daily |
| VFMO · VANGUARD WELLINGTON FUND | 0.05% | 25,265 SH | Aug. 19, 2026 | Daily |
| DFAS · Dimensional ETF Trust | 0.03% | 145,920 NS | July 31, 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.03% | 759,354 SH | Aug. 19, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.03% | 128,886 SH | Aug. 19, 2026 | Daily |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.02% | 20,725 SH | Sept. 30, 2026 | Daily |
| FHLC · FIDELITY COVINGTON TRUST | 0.02% | 20,341 NS | July 31, 2026 | N-PORT |
| WSML · iShares Trust | 0.01% | 2,757 SH | Sept. 11, 2026 | Daily |
| TILT · FlexShares Trust | 0.01% | 5,214 NS | July 31, 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.01% | 5,306 NS | July 31, 2026 | N-PORT |
| ITOT · iShares Trust | 0.00% | 92,764 SH | Sept. 11, 2026 | Daily |
| DFAU · Dimensional ETF Trust | 0.00% | 10,449 NS | July 31, 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.00% | 39,169 NS | July 31, 2026 | N-PORT |
| IWV · iShares Trust | 0.00% | 15,089 SH | Sept. 10, 2026 | Daily |
| DFUS · Dimensional ETF Trust | 0.00% | 7,498 NS | July 31, 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 1,934,442 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 5,315 SH | Aug. 19, 2026 | Daily |
| ISCB · iShares Trust | · | 2,430 SH | Sept. 11, 2026 | Daily |
| SMLF · iShares Trust | · | 63,574 SH | Sept. 11, 2026 | Daily |
VERA Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 20 analysts
BUY
Median target
$81.50
+167.9%
7 35.0%
Strong Buy
11 55.0%
Buy
2 10.0%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
14 analysts · 2026-10-01Mean target $77.50 +154.8%
← Below all targets
Current price $30.42
Low$34.00
Mean$77.50
High$100.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| VERA | · | -10.9 | · | · | -55.9% | · |
| SLS | $577M | -15.1 | · | · | -55.4% | · |
| VRDN | $3.17B | -7.7 | 23359.9% | -483.6% | -55.4% | · |
| RXRX | $2.16B | -2.8 | 26.9% | -863.4% | -62.9% | · |
| ADMA | $4.34B | 30.4 | 19.6% | 28.8% | 33.6% | 57.4% |
| MLYS | $2.96B | -15.8 | · | · | -32.2% | · |
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | · |
| VCEL | $1.82B | 112.5 | 16.4% | 6.0% | 5.0% | 74.4% |
| ZBIO | $1.98B | -4.3 | 100.0% | -3777.4% | -156.8% | · |
| BHVN | $1.50B | -1.6 | · | · | -310.8% | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 10, 2026